14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SGHT vs WOK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.59 (N/M Forward P/E, -20.2% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin).
Defensive Composite Rating Caution: Although SGHT compares more favorably head-to-head, both SGHT (35.1/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGHT vs WOK. Trailing 12-month operating profitability (SGHT -20.2% vs WOK -41.7%) and valuation multiples (SGHT N/M vs WOK N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $5.4M market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment58.7% of Rev ($6.3M)
90D Engineering Disclosures0 Published
Investor FAQ SGHT vs WOK Key Questions & Quantitative Answers
As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.59 (N/M Forward P/E, -20.2% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin). Defensive Composite Rating Caution: Although SGHT compares more favorably head-to-head, both SGHT (35.1/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
SGHT leads the Growth & Scale pillar: SGHT posts +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin), compared with WOK at +19.1% YoY revenue growth and -95.0% YoY earnings growth on $11M TTM revenue (17.0% gross margin, -41.7% operating margin). On trailing 12-month operating scale, SGHT generates $88M in USD-normalized revenue versus $11M for WOK. In operating R&D and SG&A reinvestment, SGHT deploys N/A (0 90-day corporate R&D disclosures) versus 58.7% of Rev ($6.3M) (0 disclosures) for WOK.
WOK screens cheaper on headline valuation multiples. SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-19.1% FCF margin), whereas WOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-31.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGHT (-50.1% ROE) versus WOK (-19.2% ROE) capital efficiency.
In options market volatility and institutional positioning, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 45% Vol realized risk). By comparison, WOK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (38.49β · 153% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.